165 related articles for article (PubMed ID: 37970108)
1. Classification of patients with metastatic colorectal cancer into consensus molecular subtypes into real-world: A pilot study.
González-Montero J; Burotto M; Valenzuela G; Mateluna D; Buen-Abad F; Toro J; Barajas O; Marcelain K
World J Clin Oncol; 2023 Oct; 14(10):409-419. PubMed ID: 37970108
[TBL] [Abstract][Full Text] [Related]
2. Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in
Stahler A; Hoppe B; Na IK; Keilholz L; Müller L; Karthaus M; Fruehauf S; Graeven U; Fischer von Weikersthal L; Goekkurt E; Kasper S; Kind AJ; Kurreck A; Alig AHS; Held S; Reinacher-Schick A; Heinemann V; Horst D; Jarosch A; Stintzing S; Trarbach T; Modest DP
J Clin Oncol; 2023 Jun; 41(16):2975-2987. PubMed ID: 37018649
[TBL] [Abstract][Full Text] [Related]
3. Consensus molecular subtype classification of colorectal adenomas.
Komor MA; Bosch LJ; Bounova G; Bolijn AS; Delis-van Diemen PM; Rausch C; Hoogstrate Y; Stubbs AP; de Jong M; Jenster G; van Grieken NC; Carvalho B; Wessels LF; Jimenez CR; Fijneman RJ; Meijer GA;
J Pathol; 2018 Nov; 246(3):266-276. PubMed ID: 29968252
[TBL] [Abstract][Full Text] [Related]
4. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
Mooi JK; Wirapati P; Asher R; Lee CK; Savas P; Price TJ; Townsend A; Hardingham J; Buchanan D; Williams D; Tejpar S; Mariadason JM; Tebbutt NC
Ann Oncol; 2018 Nov; 29(11):2240-2246. PubMed ID: 30247524
[TBL] [Abstract][Full Text] [Related]
5. Consensus molecular subtypes (CMS) in metastatic colorectal cancer - personalized medicine decision.
Rebersek M
Radiol Oncol; 2020 May; 54(3):272-277. PubMed ID: 32463385
[TBL] [Abstract][Full Text] [Related]
6. [Characterization of patients with sporadic colorectal cancer following the new Consensus Molecular Subtypes (CMS)].
Wielandt AM; Villarroel C; Hurtado C; Simian D; Zamorano D; Martínez M; Castro M; Vial MT; Kronberg U; López-Kostner F
Rev Med Chil; 2017 Apr; 145(4):419-430. PubMed ID: 28748988
[TBL] [Abstract][Full Text] [Related]
7. Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial).
Stahler A; Heinemann V; Schuster V; Heinrich K; Kurreck A; Gießen-Jung C; Fischer von Weikersthal L; Kaiser F; Decker T; Held S; Graeven U; Schwaner I; Denzlinger C; Schenk M; Neumann J; Kirchner T; Jung A; Kumbrink J; Stintzing S; Modest DP
Eur J Cancer; 2021 Nov; 157():71-80. PubMed ID: 34507244
[TBL] [Abstract][Full Text] [Related]
8. Consensus molecular subtype transition during progression of colorectal cancer.
van de Weerd S; Torang A; Zwager LW; Koelink PJ; Koster J; Bastiaansen BA; Lammers V; Longobardi C; Roodhart JM; van Krieken JH; Farina Sarasqueta A; Dekker E; Medema JP
J Pathol; 2023 Nov; 261(3):298-308. PubMed ID: 37681286
[TBL] [Abstract][Full Text] [Related]
9. Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer.
Okita A; Takahashi S; Ouchi K; Inoue M; Watanabe M; Endo M; Honda H; Yamada Y; Ishioka C
Oncotarget; 2018 Apr; 9(27):18698-18711. PubMed ID: 29721154
[TBL] [Abstract][Full Text] [Related]
10. Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancer.
Eide PW; Moosavi SH; Eilertsen IA; Brunsell TH; Langerud J; Berg KCG; Røsok BI; Bjørnbeth BA; Nesbakken A; Lothe RA; Sveen A
NPJ Genom Med; 2021 Jul; 6(1):59. PubMed ID: 34262039
[TBL] [Abstract][Full Text] [Related]
11. Clinical Value of Consensus Molecular Subtypes in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Ten Hoorn S; de Back TR; Sommeijer DW; Vermeulen L
J Natl Cancer Inst; 2022 Apr; 114(4):503-516. PubMed ID: 34077519
[TBL] [Abstract][Full Text] [Related]
12. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
[TBL] [Abstract][Full Text] [Related]
13. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies.
Sveen A; Bruun J; Eide PW; Eilertsen IA; Ramirez L; Murumägi A; Arjama M; Danielsen SA; Kryeziu K; Elez E; Tabernero J; Guinney J; Palmer HG; Nesbakken A; Kallioniemi O; Dienstmann R; Lothe RA
Clin Cancer Res; 2018 Feb; 24(4):794-806. PubMed ID: 29242316
[No Abstract] [Full Text] [Related]
14. The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications.
Soldevilla B; Carretero-Puche C; Gomez-Lopez G; Al-Shahrour F; Riesco MC; Gil-Calderon B; Alvarez-Vallina L; Espinosa-Olarte P; Gomez-Esteves G; Rubio-Cuesta B; Sarmentero J; La Salvia A; Garcia-Carbonero R
Eur J Cancer; 2019 Dec; 123():118-129. PubMed ID: 31678770
[TBL] [Abstract][Full Text] [Related]
15. Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models.
Linnekamp JF; Hooff SRV; Prasetyanti PR; Kandimalla R; Buikhuisen JY; Fessler E; Ramesh P; Lee KAST; Bochove GGW; de Jong JH; Cameron K; Leersum RV; Rodermond HM; Franitza M; Nürnberg P; Mangiapane LR; Wang X; Clevers H; Vermeulen L; Stassi G; Medema JP
Cell Death Differ; 2018 Mar; 25(3):616-633. PubMed ID: 29305587
[TBL] [Abstract][Full Text] [Related]
16. Consensus Molecular Subtypes of Colorectal Cancer and their Clinical Implications.
Thanki K; Nicholls ME; Gajjar A; Senagore AJ; Qiu S; Szabo C; Hellmich MR; Chao C
Int Biol Biomed J; 2017; 3(3):105-111. PubMed ID: 28825047
[TBL] [Abstract][Full Text] [Related]
17. Consensus molecular subtypes of colorectal cancer in clinical practice: A translational approach.
Valenzuela G; Canepa J; Simonetti C; Solo de Zaldívar L; Marcelain K; González-Montero J
World J Clin Oncol; 2021 Nov; 12(11):1000-1008. PubMed ID: 34909395
[TBL] [Abstract][Full Text] [Related]
18. Investigation of colorectal cancer in accordance with consensus molecular subtype classification.
Sawayama H; Miyamoto Y; Ogawa K; Yoshida N; Baba H
Ann Gastroenterol Surg; 2020 Sep; 4(5):528-539. PubMed ID: 33005848
[TBL] [Abstract][Full Text] [Related]
19. A modified protein marker panel to identify four consensus molecular subtypes in colorectal cancer using immunohistochemistry.
Li X; Larsson P; Ljuslinder I; Ling A; Löfgren-Burström A; Zingmark C; Edin S; Palmqvist R
Pathol Res Pract; 2021 Apr; 220():153379. PubMed ID: 33721619
[TBL] [Abstract][Full Text] [Related]
20. Characterizing heterogeneity along EMT and metabolic axes in colorectal cancer reveals underlying consensus molecular subtype-specific trends.
Sehgal M; Ramu S; Vaz JM; Ganapathy YR; Muralidharan S; Venkatraghavan S; Jolly MK
Transl Oncol; 2024 Feb; 40():101845. PubMed ID: 38029508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
